stoxline Quote Chart Rank Option Currency Glossary
  
Celldex Therapeutics, Inc. (CLDX)
22.41  -0.56 (-2.44%)    07-18 16:00
Open: 23.16
High: 23.33
Volume: 844,310
  
Pre. Close: 22.97
Low: 22.19
Market Cap: 1,488(M)
Technical analysis
2025-07-18 4:40:03 PM
Short term     
Mid term     
Targets 6-month :  28.06 1-year :  32.78
Resists First :  24.03 Second :  28.06
Pivot price 22.05
Supports First :  21.24 Second :  19.52
MAs MA(5) :  22.91 MA(20) :  21.8
MA(100) :  20.01 MA(250) :  26.09
MACD MACD :  0.6 Signal :  0.5
%K %D K(14,3) :  81.4 D(3) :  85
RSI RSI(14): 55.7
52-week High :  47 Low :  14.39
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CLDX ] has closed below upper band by 40.9%. Bollinger Bands are 4.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 23.36 - 23.5 23.5 - 23.61
Low: 21.85 - 22.03 22.03 - 22.16
Close: 22.18 - 22.44 22.44 - 22.62
Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Headline News

Tue, 08 Jul 2025
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Sat, 14 Jun 2025
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire

Thu, 12 Jun 2025
Celldex Presents Unprecedented 76 Week Results from - GlobeNewswire

Tue, 10 Jun 2025
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - GlobeNewswire

Fri, 06 Jun 2025
Celldex Strengthens Board with Ex-J&J Executive Who Led $25B Medical Device Business - Stock Titan

Fri, 09 May 2025
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 66 (M)
Held by Insiders 5.636e+007 (%)
Held by Institutions 0.3 (%)
Shares Short 9,130 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.1394e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -9 %
Return on Assets (ttm) 27.1 %
Return on Equity (ttm) -16.9 %
Qtrly Rev. Growth 7.56e+006 %
Gross Profit (p.s.) 303.07
Sales Per Share -20.36
EBITDA (p.s.) -1.55211e+008
Qtrly Earnings Growth -2.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -172 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -1.11
Price to Cash Flow 2.41
Stock Dividends
Dividend 0
Forward Dividend 7.83e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android